Farxiga HF Fast Track Designation; New Novo/Medtronic and Sanofi/Abbott Partnerships
Here is a brief preview of this blast: With the start of the 2019 EASD conference, a series of diabetes drug and device-related press releases have been observed including connected care partnerships between Novo/Medtronic and Sanofi/Abbott. Additionally, AstraZeneca announced that FDA granted Fast Track designation for dapagliflozin in worsening heart failure. Below FENIX insights and context from each respective announcement.